Inhibition of Growth of Androgen-independent DU-145 Prostate Cancer In Vivo by Luteinising Hormone-releasing Hormone Antagonist Cetrorelix and Bombesin Antagonists RC-3940-II and RC-3950-II

Author： Jungwirth A.   Pinski J.   Galvan G.   Halmos G.   Szepeshazi K.   Cai R.Z.   Groot K.   Vadillo-Buenfil M.   Schally A.V.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.33, Iss.7, 1997-06, pp. : 1141-1148

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comments to Inhibition of Growth of Androgen-independent DU-145 Prostate Cancer In Vivo by Luteinising Hormone-releasing Hormone Antagonist Cetrorelix and Bombesin Antagonists RC-3940-II and RC-3950-II, Jungwirth et al., Eur J Cancer 1997, 33(7), 114

By Schally A.V.   Jungwirth A.   Comaru-Schally A.M.  

European Journal of Cancer, Vol. 34, Iss. 7, 1998-06 ,pp. : 1135-1136

Elsevier

Access to resources Recommend Favorite

Inhibition of Growth of Androgen-independent DU-145 Prostate Cancer In Vivo by Luteinising Hormone-releasing Hormone Antagonist Cetrorelix and Bombesin Antagonists

By Limonta P.   Pratesi G.   Moretti R.M.   Montagnani Marelli M.   Motta M.   Dondi D.  

European Journal of Cancer, Vol. 34, Iss. 7, 1998-06 ,pp. : 1134-1135

Elsevier

Access to resources Recommend Favorite

Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095

By Miyazaki M.   Lamharzi N.   Schally A.V.   Halmos G.   Szepeshazi K.   Groot K.   Cai R.Z.  

European Journal of Cancer, Vol. 34, Iss. 5, 1998-04 ,pp. : 710-717

Elsevier

Access to resources Recommend Favorite

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

By Garcia Agustin  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 45-46

Informa Healthcare

Access to resources Recommend Favorite

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

By Verschraegen C.F.   Westphalen S.   Hu W.   Loyer E.   Kudelka A.   Volker P.   Kavanagh J.   Steger M.   Schulz K.-D.   Emons G.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 552-559

Elsevier

Access to resources Recommend Favorite